Trials / Terminated
TerminatedNCT01458405
Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With a Myocardial Infarction and Ischemic Left Ventricular Dysfunction
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 135 (actual)
- Sponsor
- Capricor Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Allogeneic Cardiosphere-Derived Cells (CAP-1002) is safe and effective in decreasing infarct size in patients with a myocardial infarction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CAP-1002 Allogeneic Cardiosphere-Derived Cells | Single dose, blinded, intracoronary infusion of 25 Million cardiosphere-derived cells |
| DRUG | Placebo | Single, blinded, intracoronary infusion of a placebo solution |
Timeline
- Start date
- 2012-11-13
- Primary completion
- 2017-07-03
- Completion
- 2019-02-28
- First posted
- 2011-10-24
- Last updated
- 2024-04-09
- Results posted
- 2024-04-09
Locations
32 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01458405. Inclusion in this directory is not an endorsement.